<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Using 7-amino-<z:chebi fb="0" ids="27666">actinomycin-D</z:chebi>/pyronin Y (7AAD/PY), we analyzed the surface phenotypes and cell cycle of 22 hematopoietic cell lines based on their cellular DNA/<z:chebi fb="40" ids="33697">RNA</z:chebi> content </plain></SENT>
<SENT sid="1" pm="."><plain>Populations of G1a, G1b, S, and G2M, the DNA index (DI), and the <z:chebi fb="40" ids="33697">RNA</z:chebi> index of S phase (SRI) were calculated by means of DNA/<z:chebi fb="40" ids="33697">RNA</z:chebi> dot plots </plain></SENT>
<SENT sid="2" pm="."><plain>Two new parameters were extracted from the cell-cycle profiles: the nucleic acid index of S phase (NI) and the coefficient of variations in the <z:chebi fb="40" ids="33697">RNA</z:chebi> at S phase (SVC) </plain></SENT>
<SENT sid="3" pm="."><plain>DNA/<z:chebi fb="40" ids="33697">RNA</z:chebi> dot plots of cell lines revealed four characteristic profiles of the cell cycle, defined with the calculated NI and SCV </plain></SENT>
<SENT sid="4" pm="."><plain>These were type 0 (small NI, large SCV), type I (small NI, small SCV), type II (large NI, small SCV), and type III (large NI, large SCV) </plain></SENT>
<SENT sid="5" pm="."><plain>Type O included four stem cell lines: one t(1;19) <z:hpo ids='HP_0001909'>leukemia</z:hpo>, two Ph1+ <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL), and one biphenotypic crisis of <z:hpo ids='HP_0011010'>chronic</z:hpo> granulocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>Type I included five ALL cell lines: three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and two common <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Type II contained 10 myeloid cell lines: five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and five myeloid crisis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Type III contained three relatively immature <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines: two Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one follicular center <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Calculated NI/SCV (%) were as follows: type 0, 2.27 +/- 0.19/16.7 +/- 3.7; type I, 2.20 +/- 0.30/11.1 +/- 0.7; type II, 3.64 +/- 0.52/11.8 +/- 1.0; and type III, 3.60 +/- 0.53/17.5 +/- 1.9 </plain></SENT>
<SENT sid="10" pm="."><plain>Cell-cycle analysis of blasts using 7AAD/PY combined with surface phenotyping may yield important information for classifying <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancy</z:e> within 2 hours of patient admission </plain></SENT>
</text></document>